The U.K.-based Institute of Cancer Research and Cancer Research Technology Ltd. are collaborating with Janssen to target an undisclosed step in the unfolded protein response in multiple myeloma. Previous results from the U.K. team have suggested the kinase domain of IRE1 as a potential target in the pathway.